-Arlene H Sharpe Researcher Activity Profile

Research Author Detailed Information 

Arlene H Sharpe Publication Rate By Year

Arlene H Sharpe has published 2 paper(s) in 2006, 12 paper(s) in 2007, 1 paper(s) in 2008, for a total of 15 research publications in total.

Arlene H Ah Sharpe Author Information

LAST NAME: sharpe

FIRST NAME: Arlene H

INITIALS: ah

AFFILIATION:

Papers

Arlene H Sharpe's Publication Record

1. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. gordon_freeman@dfci.harvard.edu
2. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Year Published: 2006
Immunology Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass 02115, USA.
3. Development of autoimmunity in mice lacking DNA topoisomerase 3beta. Year Published: 2007
Department of Molecular and Cellular Biology, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138, USA.
4. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Year Published: 2007
Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
5. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Year Published: 2007
Emory Vaccine Center and Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
6. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. Year Published: 2007
Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
7. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
8. Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles. Year Published: 2007
Laboratory of Molecular Autoimmune Disease, Renal Division, and.
9. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
10. TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
11. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. Year Published: 2007
Laboratory of Molecular Autoimmune Disease, Renal Division, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
12. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA.
13. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. Year Published: 2007
Laboratory of Molecular Autoimmune Disease, Renal Division, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
14. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA.
15. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. Year Published: 2008
Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.